Side-by-side · Research reference
MGFvsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/55 cited
BPhase 2HUMAN-REVIEWED8/46 cited
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
MGF
TB-500
Primary target
Satellite cells (Pax7+) in skeletal muscleMoore 2018
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
—
Endogenous protein at baseline; supplementation amplifies
Origin
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—
02Dosage Protocols
Parameter
MGF
TB-500
Synthetic peptide
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
—
Rodent cardiac model
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
—
Acute delivery (mouse MI)
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
—
Human evidence
None — no published clinical trials
All dosing extrapolated from animal models.
—
Detection in doping
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
—
Evidence basis
Animal models + in vitro only
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Standard dose
—
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
—
2× per week (loading); then 1× per week (maintenance)
Lower / starter dose
—
1 mg per injection
Duration
—
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
—
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
—
Evening or pre-rest preferred (anecdotal)
Half-life
—
~2 hours (estimated; tissue uptake longer)
04Side Effects & Safety
Parameter
MGF
TB-500
Human safety data
None — no clinical trials published
—
Theoretical IGF-1 axis risk
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
—
Tumor promotion
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
—
Antibody development
Unknown — no longitudinal human exposure data
—
Local injection reaction
Presumed similar to other peptides (erythema, induration) — no direct evidence
—
Dysregulated expression with age
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
—
Injection site reaction
—
Mild erythema, transient pain
GI symptoms
—
Rare nausea (anecdotal)
Cancer risk
—
Theoretical via angiogenesis pathway
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Pregnancy / OB
—
Avoid
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
MGF
TB-500
1. No validated protocol
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Synthetic peptide form
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Animal delivery models
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
Evening or pre-sleep is most common anecdotal timing.
4. WADA prohibition
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Research context only
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair